within Pharmacolibrary.Drugs.ATC.C;

model C09CA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 3.5833333333333335e-05,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0179,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019166666666666665,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0414,
    k12             = 5.3,
    k21             = 5.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09CA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Valsartan is an angiotensin II receptor blocker (ARB) used in the management of hypertension, heart failure, and to improve survival after myocardial infarction. It is approved for use by regulatory agencies globally and is in active clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model for healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Yang, SJ, et al., &amp; Han, HK (2016). Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. <i>Biopharmaceutics &amp; drug disposition</i> 37(5) 245–251. DOI:<a href=\"https://doi.org/10.1002/bdd.2001\">10.1002/bdd.2001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26663350/\">https://pubmed.ncbi.nlm.nih.gov/26663350</a></p></li><li><p>Uijl, E, et al., &amp; Danser, AHJ (2019). Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. <i>Hypertension (Dallas, Tex. : 1979)</i> 73(6) 1249–1257. DOI:<a href=\"https://doi.org/10.1161/HYPERTENSIONAHA.119.12703\">10.1161/HYPERTENSIONAHA.119.12703</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31030610/\">https://pubmed.ncbi.nlm.nih.gov/31030610</a></p></li><li><p>Gu, J, et al., &amp; Dole, WP (2010). Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). <i>Journal of clinical pharmacology</i> 50(4) 401–414. DOI:<a href=\"https://doi.org/10.1177/0091270009343932\">10.1177/0091270009343932</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19934029/\">https://pubmed.ncbi.nlm.nih.gov/19934029</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09CA03;
